Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
242.61
+0.64 (0.26%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Alnylam Pharmaceuticals Stock Forecast
Stock Price Forecast
The 23 analysts with 12-month price forecasts for Alnylam Pharmaceuticals stock have an average target of 322.39, with a low estimate of 220 and a high estimate of 500. The average target predicts an increase of 32.88% from the current stock price of 242.61.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Alnylam Pharmaceuticals stock from 24 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 10 | 10 | 11 | 11 |
| Buy | 7 | 7 | 8 | 8 | 9 | 9 |
| Hold | 5 | 5 | 5 | 4 | 3 | 3 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 23 | 23 | 24 | 23 | 24 | 24 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $284 → $268 | Hold | Maintains | $284 → $268 | +10.47% | Apr 11, 2025 |
| Needham | Needham | Strong Buy Reiterates $320 | Strong Buy | Reiterates | $320 | +31.90% | Apr 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $500 | Strong Buy | Reiterates | $500 | +106.09% | Apr 2, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $338 → $342 | Buy | Maintains | $338 → $342 | +40.97% | Mar 31, 2025 |
| Redburn Atlantic | Redburn Atlantic | Strong Buy Initiates $353 | Strong Buy | Initiates | $353 | +45.50% | Mar 31, 2025 |
Financial Forecast
Revenue This Year
2.95B
from 2.25B
Increased by 31.17%
Revenue Next Year
3.69B
from 2.95B
Increased by 24.99%
EPS This Year
-1.76
from -2.18
EPS Next Year
0.75
from -1.76
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.6B | 4.6B | 6.3B | ||
| Avg | 2.9B | 3.7B | 4.7B | ||
| Low | 2.4B | 3.0B | 3.7B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 62.2% | 56.1% | 70.1% | ||
| Avg | 31.2% | 25.0% | 28.8% | ||
| Low | 7.9% | 3.0% | -0.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.13 | 5.02 | 12.39 | ||
| Avg | -1.76 | 0.75 | 5.77 | ||
| Low | -3.59 | -2.43 | 2.41 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 1,558.7% | ||
| Avg | - | - | 671.9% | ||
| Low | - | - | 222.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.